Streetbeat News

Products Services

EYPT

GTLB

HUT

TSLA

TTWO

U.S. stocks fell on Monday, with the Dow Jones down 0.11%, NASDAQ down 0.84%, and S&P 500 down 0.54%. EyePoint Pharmaceuticals soared 177.46% after positive trial results. Hut 8 Mining dropped 11.75% post-business combination. GitLab rose 0.88% on strong Q3 results. Take-Two Interactive slightly fell 0.18% after revealing GTA 6's first female lead. Tesla declined 1.36% amid Cybertruck pricing discussions.

Portfolio Pulse from Benzinga Neuro

December 05, 2023 | 2:23 am

LLY

NVO

RHHBY

Jim Cramer highlighted the 'transformational' impact of GLP-1 weight loss drugs like Ozempic, suggesting investors focus on potential winners from the growing demand for these drugs. Eli Lilly (LLY) and Novo Nordisk (NVO), manufacturers of GLP-1 drugs, are immediate beneficiaries. Other sectors like high-protein food manufacturers and construction companies for pharmaceutical facilities, as well as the apparel sector, could also benefit. Roche Holding AG (RHHBY) has entered the competition by acquiring Carmot Therapeutics, indicating a heated market for obesity treatment drugs.

Portfolio Pulse from Benzinga Neuro

December 05, 2023 | 1:24 am

TTWO

Rockstar Games, a subsidiary of Take Two Interactive Software Inc (NASDAQ:TTWO), released the official trailer for 'Grand Theft Auto VI' (GTA 6), confirming a 2025 release and introducing the first female lead, Lucia. The trailer, which was moved up due to a leak, showcases Vice City, social media integration, and hints at teamwork in the game's narrative. Take-Two Interactive has hinted at significant financial gains expected from the game's release between April 2024 and March 2025.

Portfolio Pulse from Franca Quarneti

December 05, 2023 | 12:38 am

WBD

Former Congressman George Santos, ousted from the House of Representatives amid allegations and federal charges, has joined Cameo, offering video messages for $200 each. Warner Bros. Discovery's HBO Films unit has optioned the rights to a book about Santos for a movie. The book, 'The Fabulist,' details Santos' controversial career and was released on Nov. 28, 2023. Frank Rich is set to work on the movie, which will take a 'darkly comic look' at Santos' story.

Portfolio Pulse from Chris Katje

December 04, 2023 | 11:38 pm

TTWO

Rockstar Games, a subsidiary of Take-Two Interactive Software, Inc. (TTWO), experienced a leak of their trailer, prompting them to direct audiences to watch the official version on YouTube. The company addressed the situation via a Twitter post.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 11:21 pm

VNDA

Vanda Pharmaceuticals announced that the FDA has accepted its New Drug Application for Tradipitant, aimed at treating Gastroparesis. The FDA's decision is expected by September 18, 2024. If approved, Tradipitant would be the first novel drug for Gastroparesis approved in over 40 years.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 11:02 pm

ETCUSD

ETHUSD

The article discusses Ethereum's (ETH) potential to make investors millionaires if it returns to its all-time high. Ethereum, launched in 2015, has seen significant events like the Ethereum 2.0 fork, interest in NFTs, and a transition from proof-of-work to proof-of-stake. Despite the 2022 crypto company bankruptcies, Ethereum's price is up 12% over the last week and 80% YTD in 2023. To become a millionaire at Ethereum's all-time high, an investor would need 204.43 ETH, costing $456,338.87 today. However, there's no guarantee of Ethereum's price increase.

Portfolio Pulse from Chris Katje

December 04, 2023 | 10:12 pm

NPCE

NeuroPace has entered into a strategic collaboration to provide biomarker monitoring and data analysis capabilities using its RNS System. A clinical-stage biotechnology company will pay NeuroPace up to $3.7 million over two years for non-exclusive access to these services for its clinical trial patients.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 10:09 pm

NPCE

NeuroPace, Inc. has entered into a collaboration with Rapport Therapeutics to share site data for Rapport's Phase 2a trial of their GABA A receptor-associated protein compound.

Portfolio Pulse from Charles Gross

December 04, 2023 | 10:09 pm

CTSH

The University of Melbourne has selected Cognizant (CTSH) to develop data-driven and personalized experiences for students, staff, and alumni to improve engagement.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 10:01 pm